| Edward S Rittweger, MD | |
|
1500 Saint Georges Ave, Avenel, NJ 07001-1000 | |
| (732) 381-8686 | |
| (732) 499-7724 |
| Full Name | Edward S Rittweger |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 47 Years |
| Location | 1500 Saint Georges Ave, Avenel, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184621625 | NPI | - | NPPES |
| 1426001 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 25MA03475600 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayshore Medical Center | Holmdel, NJ | Hospital |
| Jfk Medical Center | Edison, NJ | Hospital |
| Jersey Shore University Medical Center | Neptune, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Imaging Llc | 8123312055 | 47 |
News Archive
In an effort to identify and treat patients with undiagnosed depression, Cedars-Sinai nurses are screening each hospitalized patient for signs of the illness and for risk factors that could make recoveries harder and longer.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the Hebrew University, introduces a novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy.
Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Rutgers researchers, with the aid of $2.5 million National Institute of Environmental Health Sciences grant, will study how exposure to cadmium during pregnancy can impact fetal development.
› Verified 5 days ago
| Entity Name | Avenel Iselin Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487674867 PECOS PAC ID: 5597751941 Enrollment ID: O20040422000098 |
News Archive
In an effort to identify and treat patients with undiagnosed depression, Cedars-Sinai nurses are screening each hospitalized patient for signs of the illness and for risk factors that could make recoveries harder and longer.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the Hebrew University, introduces a novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy.
Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Rutgers researchers, with the aid of $2.5 million National Institute of Environmental Health Sciences grant, will study how exposure to cadmium during pregnancy can impact fetal development.
› Verified 5 days ago
| Entity Name | Health Village Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194810978 PECOS PAC ID: 9537263223 Enrollment ID: O20070406000359 |
News Archive
In an effort to identify and treat patients with undiagnosed depression, Cedars-Sinai nurses are screening each hospitalized patient for signs of the illness and for risk factors that could make recoveries harder and longer.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the Hebrew University, introduces a novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy.
Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Rutgers researchers, with the aid of $2.5 million National Institute of Environmental Health Sciences grant, will study how exposure to cadmium during pregnancy can impact fetal development.
› Verified 5 days ago
| Entity Name | The New Jersey Imaging Network, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629327887 PECOS PAC ID: 2860633492 Enrollment ID: O20130724000791 |
News Archive
In an effort to identify and treat patients with undiagnosed depression, Cedars-Sinai nurses are screening each hospitalized patient for signs of the illness and for risk factors that could make recoveries harder and longer.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the Hebrew University, introduces a novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy.
Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Rutgers researchers, with the aid of $2.5 million National Institute of Environmental Health Sciences grant, will study how exposure to cadmium during pregnancy can impact fetal development.
› Verified 5 days ago
| Entity Name | Coastal Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710334727 PECOS PAC ID: 8123312055 Enrollment ID: O20160816000083 |
News Archive
In an effort to identify and treat patients with undiagnosed depression, Cedars-Sinai nurses are screening each hospitalized patient for signs of the illness and for risk factors that could make recoveries harder and longer.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the Hebrew University, introduces a novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy.
Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Rutgers researchers, with the aid of $2.5 million National Institute of Environmental Health Sciences grant, will study how exposure to cadmium during pregnancy can impact fetal development.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edward S Rittweger, MD 1500 Saint Georges Ave, Avenel, NJ 07001-1000 Ph: (732) 381-8686 | Edward S Rittweger, MD 1500 Saint Georges Ave, Avenel, NJ 07001-1000 Ph: (732) 381-8686 |
News Archive
In an effort to identify and treat patients with undiagnosed depression, Cedars-Sinai nurses are screening each hospitalized patient for signs of the illness and for risk factors that could make recoveries harder and longer.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the Hebrew University, introduces a novel method for detecting retinal micro-aneurysms that pose a high risk for leakage, an underlying cause of diabetic retinopathy.
Onconova Therapeutics, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon- (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Rutgers researchers, with the aid of $2.5 million National Institute of Environmental Health Sciences grant, will study how exposure to cadmium during pregnancy can impact fetal development.
› Verified 5 days ago
Leo J Fontana, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 Saint Georges Ave, Avenel, NJ 07001 Phone: 732-381-8686 Fax: 732-499-7724 | |
David G Wirtshafter, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 Saint Georges Ave, Avenel, NJ 07001 Phone: 732-381-8686 Fax: 732-499-7724 | |
Mark Singer, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 Saint Georges Ave, Avenel, NJ 07001 Phone: 732-381-8686 Fax: 732-499-7724 | |
Charles A Saniewski, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 Saint Georges Ave, Avenel, NJ 07001 Phone: 732-381-8686 Fax: 732-499-7724 | |
Dr. Peter S Doss, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 Saint Georges Ave, Avenel, NJ 07001 Phone: 732-574-8999 Fax: 732-574-3488 | |
Robert Bashkim Limani, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 Saint Georges Ave, Avenel, NJ 07001 Phone: 732-381-8686 Fax: 732-499-7724 |